Botanix Pharmaceuticals Ltd (AU:BOT) — Market Cap & Net Worth
Market Cap & Net Worth: Botanix Pharmaceuticals Ltd (BOT)
Botanix Pharmaceuticals Ltd (AU:BOT) has a market capitalization of $32.07 Million (AU$45.33 Million) as of June 17, 2026. Listed on the AU stock exchange, this Australia-based company holds position #23585 globally and #907 in its home market, demonstrating a 4.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Botanix Pharmaceuticals Ltd's stock price AU$0.02 by its total outstanding shares 1970659977 (1.97 Billion). Review Botanix Pharmaceuticals Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
Botanix Pharmaceuticals Ltd Market Cap History: 2015 to 2026
Botanix Pharmaceuticals Ltd's market capitalization history from 2015 to 2026. Data shows change from $25.10 Million to $32.07 Million (-0.40% CAGR).
Botanix Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Botanix Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
32.52x
Botanix Pharmaceuticals Ltd's market cap is 32.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $92.03 Million | $46.50K | -$4.77 Million | 1979.10x | N/A |
| 2018 | $97.61 Million | $1.78 Million | -$11.01 Million | 54.90x | N/A |
| 2019 | $114.34 Million | $4.69 Million | -$17.04 Million | 24.40x | N/A |
| 2020 | $174.30 Million | $7.57 Million | -$16.73 Million | 23.01x | N/A |
| 2021 | $78.08 Million | $6.89 Million | -$3.33 Million | 11.34x | N/A |
| 2022 | $73.90 Million | $2.75 Million | -$13.17 Million | 26.82x | N/A |
| 2023 | $264.93 Million | $914.97K | -$9.15 Million | 289.55x | N/A |
| 2024 | $606.55 Million | $601.82K | -$13.87 Million | 1007.86x | N/A |
| 2025 | $188.24 Million | $5.79 Million | -$86.40 Million | 32.52x | N/A |
Competitor Companies of BOT by Market Capitalization
Companies near Botanix Pharmaceuticals Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to Botanix Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Botanix Pharmaceuticals Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Botanix Pharmaceuticals Ltd's market cap moved from $25.10 Million to $ 32.07 Million, with a yearly change of -0.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$32.07 Million | -82.96% |
| 2025 | AU$188.24 Million | -68.97% |
| 2024 | AU$606.55 Million | +128.95% |
| 2023 | AU$264.93 Million | +258.49% |
| 2022 | AU$73.90 Million | -5.36% |
| 2021 | AU$78.08 Million | -55.20% |
| 2020 | AU$174.30 Million | +52.44% |
| 2019 | AU$114.34 Million | +17.14% |
| 2018 | AU$97.61 Million | +6.06% |
| 2017 | AU$92.03 Million | +50.00% |
| 2016 | AU$61.35 Million | +144.44% |
| 2015 | AU$25.10 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Botanix Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.07 Million USD |
| MoneyControl | $32.07 Million USD |
| MarketWatch | $32.07 Million USD |
| marketcap.company | $32.07 Million USD |
| Reuters | $32.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more